Septerna Reports Strong Q1 Financials with Reduced Net Loss and Confirmed Cash Runway into 2029; CMO Departs
SEPN has more than doubled off its 52-week low of $6.44.
Summary
Septerna reported strong Q1 2026 financial results, including a significant revenue increase and reduced net loss, while confirming its cash runway into 2029, alongside the departure of its Chief Medical Officer.
Key Events · Earnings and Guidance · SEPN
-
Strong Q1 Financial Performance
Revenue surged to $26.5 million in Q1 2026 from $0.2 million in Q1 2025, primarily due to the Novo Nordisk collaboration. Net loss significantly decreased to $8.6 million from $21.5 million year-over-year.
-
Extended Cash Runway Confirmed
The company reported a cash position of $522.1 million as of March 31, 2026, which is expected to fund operations at least into 2029, reinforcing its financial stability.
-
Chief Medical Officer Departure
Dr. Jae Kim, Chief Medical Officer, is leaving to pursue a new opportunity. He will serve in an advisory capacity during the transition, and a search for his successor has begun.
-
Pipeline Progress Highlighted
The company reiterated positive Phase 1 data for SEP-631, supporting Phase 2b development, and the initiation of a Phase 1 trial for SEP-479, with data expected in late 2026 or early 2027.
Analysis · SEPN · Life Sciences
Septerna's first-quarter results demonstrate significant financial improvement, with a substantial increase in revenue driven by its collaboration with Novo Nordisk and a notable reduction in net loss. This strong performance, coupled with a confirmed cash runway extending into 2029, provides a solid financial foundation for the clinical-stage biotech. The departure of the Chief Medical Officer is a key executive change, but the stated reason and advisory role during transition mitigate immediate concerns.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1427 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $23.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.44 to $32.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.